Jefferies Group’s Travere Therapeutics TVTX Stock Holding History

Jefferies Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-25,000	Closed	-$510	–	1549
2020 Q2	$510	Buy	+25,000	New	+$398K	0.01%	913
2019 Q4	–	Sell	-18,832	Closed	-$218K	–	3018
2019 Q3	$218K	Buy	18,832 +6,678	+55%	+$110K	﹤0.01%	2322
2019 Q2	$244K	Sell	12,154 -7,060	-37%	-$139K	﹤0.01%	2034
2019 Q1	$435K	Sell	19,214 -10,256	-35%	-$227K	﹤0.01%	1650
2018 Q4	$667K	Sell	29,470 -20,530	-41%	-$511K	0.01%	1355
2018 Q3	$1.44M	Buy	+50,000	New	+$1.43M	0.01%	1138
2016 Q4	–	Sell	-1,906	Closed	-$43K	–	2491
2016 Q3	$43K	Sell	1,906 -58,089	-97%	-$1.11M	﹤0.01%	2102
2016 Q2	$1.07M	Sell	59,995 -24,060	-29%	-$389K	﹤0.01%	1122
2016 Q1	$1.15M	Buy	+84,055	New	+$1.28M	0.01%	1081

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jefferies Group's TVTX Position: Q3 2020 in Review

Jefferies Group sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 25,000 shares — an estimated $510 sold.

Jefferies Group first reported a position in TVTX in Q1 2016 and held it in 9 quarters. The position peaked at $1.44M in Q3 2018. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

Jefferies Group reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
Jefferies Group sold 25,000 Travere Therapeutics shares in Q3 2020, an estimated $510.
Jefferies Group first reported a position in Travere Therapeutics in Q1 2016 and held it in 9 quarters.
Jefferies Group's Travere Therapeutics position peaked at $1.44M in Q3 2018.
134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.